PPM1D and plasma cell myeloma: After several chemotherapy lines, HDCT and ASCT, the prevalence of truncating PPM1D gene mutations in the peripheral blood of myeloma patients emerged at 1.3% after the first HDCT/ASCT and 7.3% after the second HDCT/ASCT procedure.